logo-loader
Aequus Pharmaceuticals Inc

Aequus Pharmaceuticals signs deal with world-renowned eye clinic to use Zepto system in cataract surgeries

Zepto will be used in one of the top clinics in Canada, where more than 10,000 cataract surgeries are performed every year

zepto
Zepto provides consistent, high quality anterior lens capsulotomies during cataract surgery in a cost-effective, disposable format

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) announced Thursday that its cataract technology system, Zepto Capsulotomy, will be used at the world-renowned Kensington Eye Institute.

The Zepto Capsulotomy system provides consistent, high-quality anterior lens capsulotomies during cataract surgery in a cost-effective, disposable format.

Based in Toronto, the Kensington Eye Institute is a leader in Canada for cataract, glaucoma and retina surgery. Home to some of the top eye surgeons in the country, Kensington pioneers the introduction and development of new ophthalmology technologies.

READ: Aequus Pharmaceuticals brings in $2.35 million after closing offering

“The Zepto Capsulotomy System has received positive feedback with our customers in specific types of cataract surgeries,” said Ian Ball, CCO of Aequus.

“We’re proud to have the Zepto placed in one of the top clinics in Canada, where over 10,000 cataract surgeries are performed every year. This placement, along with the extension of the distribution agreement, provides further validation of Aequus’ ability to successfully commercialize assets within Canada.”

Aequus also announced it had extended its agreement with Mynosys Cellular Devices Inc to distribute Zepto in Canada to April 2022.

The company said the supplier relationship "does not imply any endorsement of the product nor imply a broader strategic relationship" between the parties.

Based in Vancouver, Aequus has several commercial products in ophthalmology and transplant in its pipeline and a development stage pipeline in neurology and psychiatry. Its most recent addition to the pipeline was a long-acting form of medical cannabis.

—(Updates with disclaimer)—

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Aequus Pharmaceuticals Inc

Price: $0.15

Market: TSX-V
Market Cap: $12.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye

Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye. 

on 13/3/19

2 min read